Abstract 995P
Background
Our real-world study aimed to assess the current treatment landscape of aHCC in Ontario, Canada.
Methods
This retrospective cohort study used provincial-level databases from Ontario, Canada to identify patients diagnosed with aHCC between April 2010 and March 2019 with follow-up data available until March 2020. De novo stage IV disease and/or receipt of first line (1L) systemic therapy (ST) was used to establish an aHCC diagnosis. Baseline characteristics, treatment patterns, clinical outcomes, health care resource utilization and costs (in 2020 Canadian dollars) were determined.
Results
A total of 7,322 patients were identified using HCC diagnosis codes, of which 802 met the aHCC diagnosis criteria (82% male, median age 66 years). More than half (N=427) received 1L STs (98% sorafenib; <2% lenvatinib), a quarter (N=195) were untreated, and 9% (N=72) were given locoregional therapy without use of ST. Only 4% (N=19) of 1L treated patients were given a 2L treatment. The median time from diagnosis to 1L ST initiation was 2.3 months and median time on 1L ST was 2.4 months. Median overall survival (mOS) from diagnosis was 9.0 months (95% confidence interval [CI]: 7.8-10.3) and 2.7 months (95% CI: 2.3-3.3) for the treated and untreated cohorts, respectively. The mean total cost per 1L treated patient was $49,640, with oral medications as the main cost driver followed by inpatient hospitalizations.
Conclusions
Our study confirmed guarded prognosis of aHCC despite treatments with sorafenib, in keeping with mOS observed in clinical trials. Low uptake of 1L ST and subsequent uptake of 2L underscores high attrition rates likely related to the frailty of aHCC patients and lack of adequate ST options. Future studies will inform whether immunotherapy-based treatments in the latest years will improve ST uptake, attrition rates and health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HOPE Research Centre.
Funding
AstraZeneca Canada Inc.
Disclosure
D. Bosse: Financial Interests, Personal, Financially compensated role: Ipsen, AstraZeneca, Bayer, Pfizer, Bristol-Meyers Squibb, Amgen, Merck, Knight Therapeutics, Eisai. Y. Kim, J. Tieu, S.Z. Wang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. C. Shephard: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18